Veraxa Biotech (VRXA) Ratios
Veraxa Biotech Ratios
VRXA's free cash flow for Q1 2026 was $-149.31K. For the 2026 fiscal year, VRXA's free cash flow was increased by $0.00 and operating cash flow was $-149.31K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 0.15 | 18.28 |
| Quick Ratio | 0.15 | 18.28 |
| Cash Ratio | 0.14 | 17.15 |
| Solvency Ratio | 0.67 | 0.34 |
| Operating Cash Flow Ratio | -0.38 | -18.05 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 |
| Net Current Asset Value | $ -13.15M | $ -11.37M |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.10 | 0.95 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | -503.52% | -589.13% |
| Return on Assets (ROA) | 3.33% | 1.59% |
| Return on Equity (ROE) | 3.50% | 1.67% |
| Return on Capital Employed (ROCE) | -0.66% | -0.27% |
| Return on Invested Capital (ROIC) | -0.66% | -0.27% |
| Return on Tangible Assets | 3.33% | 1.59% |
| Earnings Yield | 3.33% | 1.55% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | -0.02 | -0.03 |
| Free Cash Flow Per Share | -0.02 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 |
| Free Cash Flow Yield | -0.18% | -0.26% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | 30.03 | 64.67 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.05 | 1.08 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -555.25 | -380.73 |
| Price-to-Operating Cash Flow Ratio | -555.25 | -380.73 |
| Price-to-Earnings Growth (PEG) Ratio | 0.21 | 0.00 |
| Enterprise Value Multiple | -151.11 | -380.06 |
| Enterprise Value | 269.77M | 267.16M |
| EV to EBITDA | -151.11 | -380.06 |
| EV to Sales | 0.00 | 0.00 |
| EV to Free Cash Flow | -554.87 | -379.78 |
| EV to Operating Cash Flow | -554.87 | -379.78 |
| Tangible Book Value Per Share | 10.15 | 9.27 |
| Shareholders’ Equity Per Share | 10.15 | 9.27 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | 0.36 | 0.15 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | -5.04 | -5.89 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | -0.05 | -0.17 |
Currency in USD
